CuraTeQ Biologics completes Phase 1 Pharmacokinetics study of biosimilar Denosumab

This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets

Ryvu advances romaciclib program as FDA clears AML trial expansion

The regulatory decision follows promising results from RIVER-81

Biocon Academy graduates 156 students at 10th convocation

The graduating cohort comprised seven batches across five specialized programs

Omnix Medical advances first-in-class antimicrobial OMN6 into Phase II trials

Targeting deadly drug-resistant acinetobacter infections

Lupin's novel cancer therapy LNP8701 shows encouraging results in phase 1 trial

First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors

Quotient Sciences advances AI-designed drug product into Phase I clinical study

Company launches clinical study of AI-designed oral formulation following MHRA approval, marking a major milestone in AI-driven drug development.

EMA accepts filing for Teva and Medincell’s long-acting schizophrenia treatment candidate

If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings

IGI’s new drug candidate ISB 2301 to target solid tumors

The company intends to file an IND submission by the end of this year and begin clinical studies in 2027

Actio Biosciences launches Phase 1b/2 trial for ultra-rare pediatric epilepsy therapy

The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process

Altasciences and Certara forge strategic pact to speed early drug development